The Pharmacy Anti-Steering and Transparency Act, which will go into effect Jan. 1, 2020, prohibits insurers and benefits managers who have ownership in a pharmacy from steering patients to that business. The law endeavors to reduce conflicts of interests, increase transparency and give patients more choice.

The law was inspired in part by local pharmacist Jennifer Shannon, who saw first-hand how coercive steering practices can negatively impact patient care.


Read More

“All eligible patients with ovarian cancer deserve informed counseling regarding the pros and cons of maintenance therapy, and the option of maintenance treatment in these regulatory approved settings.”  This article from the Oncologist provides and nice summary and valuable insight into the current state of affairs for ovarian cancer patients. Free-registration link here The Oncologist-2019-Randall-theoncologist.2019-0020

Read More

Natasha Khrystolubova is one of the lead author of the Journal of Oncology Pharmacy Practice article, Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting.

An NCODA practice working to make a difference in the pharmacy to positively impact patient care. Florida Cancer Specialists (FCL) have taken an active role in patient care and adherence.

Going Beyond the First Fill gives every patient the monitoring and follow-up to improve care at the pharmacy level through best practices. These are challenges real community-based pharmacies are facing. FCS gives patients the support needed through health education and resources. “The FCS program was designed specifically to manage AEs that occurred during use of afatinib, but many of the principles and approaches could be implemented for patients treated with other types of medication. ” Read More.

Read More